Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal

By themelower On Apr 19, 2026

Novartis S 9 Billion Bet Is Worth The Risk Wsj Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Swiss drug giant novartis bought the biotech for $9 billion last year in part because avexis had figured out how to actually make gene therapies at a big enough scale, avexis chief.

Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal Closing the all cash deal will give novartis control of a phase 3 gene therapy treatment of the rare neuromuscular disorder spinal muscular atrophy (sma), plus the resources avexis. Zurich (reuters) swiss drugmaker novartis is moving further into gene therapy by buying avexis for $8.7 billion, adding a rare disease treatment that could reap billions in sales. Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Gene therapy developer avexis will be known as novartis gene therapies, more than two years after being acquired by the swiss biopharma giant. in may 2018, novartis spent $8.7 billion to acquire gene therapy technology and therapy developer avexis.

Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Gene therapy developer avexis will be known as novartis gene therapies, more than two years after being acquired by the swiss biopharma giant. in may 2018, novartis spent $8.7 billion to acquire gene therapy technology and therapy developer avexis. Swiss pharmaceuticals company novartis plans to spend $8.7bn buying avexis, a us specialist in spinal muscular atrophy, a childhood wasting disease, in the latest strategic move by its new. On may 15, 2018, novartis announced its completed acquisition of avexis, a clinical stage gene therapy biotech company, for a total of $8.7 billion in cash through a merger of its indirect wholly owned subsidiary, novartis am merger corporation (merger sub), with and into avexis. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. On monday, novartis ceo vasant narasimhan announced the company would buy the illinois based gene therapy developer avexis for $8.7 billion.

Novartis 8 7 Billion Bet On Gene Therapy With Avexis Deal Business Swiss pharmaceuticals company novartis plans to spend $8.7bn buying avexis, a us specialist in spinal muscular atrophy, a childhood wasting disease, in the latest strategic move by its new. On may 15, 2018, novartis announced its completed acquisition of avexis, a clinical stage gene therapy biotech company, for a total of $8.7 billion in cash through a merger of its indirect wholly owned subsidiary, novartis am merger corporation (merger sub), with and into avexis. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. On monday, novartis ceo vasant narasimhan announced the company would buy the illinois based gene therapy developer avexis for $8.7 billion.

Novartis Bets Big On Gene Therapy With 8 7 Billion Avexis Deal The Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. On monday, novartis ceo vasant narasimhan announced the company would buy the illinois based gene therapy developer avexis for $8.7 billion.

Novartis Buying Avexis For 8 7b To Strengthen Gene Therapy Capabilities

Step into a world where your Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal passion takes center stage. We're thrilled to have you here with us, ready to embark on a remarkable adventure of discovery and delight.

Novartis' $8.7 billion deal for gene therapy company AveXis

Novartis' $8.7 billion deal for gene therapy company AveXis

Novartis' $8.7 billion deal for gene therapy company AveXis Novartis buying AveXis for nearly $9 billion FDA approves Novartis gene therapy for rare genetic disorder Novartis Gene Therapies how does gene therapy work - novartis' $8.7 billion deal for gene therapy company avexis AveXis, A Novartis Company Novartis Gene Therapies SMA Screening Commercialization Learnings with Novartis Gene Therapies' President Chris Fox 006 - Novartis buys Avexis! 2020 Chicago Innovation Award Winner - Novartis Gene Therapies Trending in Rare Diseases: SMA gene therapy, AATD deal and more Gene therapy company begins operations in Longmont $2 Million Gene Therapy, Is It Worth It? - Biofilm News April 2022 Cure SMA and Novartis Gene Therapies Clinical Trial Update Webinar Novartis makes $8.8bn bet on gene therapies with takeover of Avexis Gene therapy for Spinal muscular atrophy.This isn't zolgensma, it is similar gene therapy #spinraza Avexis Is Expanding Operations To North Carolina Gene Therapy For Spinal Muscular Atrophy Baby gene therapy study offers hope for fatal muscle disease ++Animation voiced++ Cure SMA's Treatment Update Webinar with Novartis

Conclusion

In summation, our exploration of Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal has unveiled a wealth of key takeaways and potential impacts. Regardless of your current level of expertise, we trust that this content has furnished you with the necessary understanding to engage with this topic confidently.

Take the next step and put this information into practice. Should you require additional guidance, be sure to check out our related articles. Your journey towards mastery of Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal is just beginning. Share your thoughts and experiences in the comments below.

Ready to take action?. Subscribe to our newsletter for exclusive content. The world of Avexis Sma Gene Therapy Manufacturing Drove 9 Billion Novartis Deal is constantly evolving, and we're here to guide you through it. Let's continue this conversation and build something remarkable together. Your feedback is invaluable, so please let us know how we can further assist you.